About

FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

FluoGuide

FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system. The lead product is FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Local cancer cells are left behind in approx. 50% of patients undergoing surgery with the intention to completely remove the cancer.

Intelligent surgical targeting, in fact, has a potential to help surgeon to reduce costs and time for any kind of surgery. 5% of the gross National Product (GNP) is spent on surgery – over EUR 1,000 billion annually. This is the market FluoGuide enters with intelligent surgical targeting.